NRx Pharmaceuticals announced the creation of a new subsidiary, NRx Defense Systems, Inc., and a partnership with Zeta Surgical to develop a mobile, frameless transcranial magnetic stimulation (TMS) system for military and first‑responder populations.
The collaboration leverages Zeta Surgical’s AI‑powered neuronavigation platform, which received FDA 510(k) clearance in October 2025, enabling robotic‑enabled TMS without the need for head fixation or general anesthesia.
NRx will combine its NRX‑101 platform—an oral D‑cycloserine/lurasidone therapy—with the TMS system to deliver neuroplastic treatment aimed at reducing PTSD and suicidal ideation among front‑line personnel.
This move expands NRx’s neuroplasticity platform beyond civilian markets into defense and emergency services, opening new revenue streams and addressing unmet needs in military and first‑responder communities.
Dr. Dennis McBride, a former defense neurotechnology leader, has been appointed president of NRx Defense Systems, underscoring the company’s commitment to the sector.
A prototype of the mobile TMS system is slated for unveiling at the Clinical TMS Society meeting in June 2026, marking a key milestone toward deployment.
Analysts view the partnership as a strategic pivot that could broaden NRx’s market reach, aligning with growing interest in neuroplastic therapies for mental health while the company remains in early development stages.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.